Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/21/18
End: 12/31/22
Due: 12/31/23
Phase: N/A
Priority: Normal
Start: 02/29/16
End: 03/31/18
Due: 03/31/19
Phase: N/A
Priority: Normal
Start: 05/31/16
End: 07/31/18
Due: 07/31/19
Phase: N/A
Priority: Normal
Start: 12/31/11
End: 12/31/14
Due: 12/31/15
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | NCT03750071 | Vaximm GmbH | user2@example.com | None | 2018-11-21 | 2022-12-31 | 2023-12-31 | - | - | 2025-07-14 |
| VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis | NCT02718430 | Vaximm GmbH | user2@example.com | None | 2016-02-29 | 2018-03-31 | 2019-03-31 | - | - | 2025-07-14 |
| VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma | NCT02718443 | Vaximm GmbH | user2@example.com | None | 2016-05-31 | 2018-07-31 | 2019-07-31 | - | - | 2025-07-14 |
| VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer | NCT01486329 | Vaximm GmbH | user2@example.com | None | 2011-12-31 | 2014-12-31 | 2015-12-31 | - | - | 2025-07-14 |